Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
View Top Employees from Kura Oncology, Inc.Website | http://www.kuraoncology.com |
Ticker | KURA |
Revenue | $807000 |
Funding | $53 million |
Employees | 171 (143 on RocketReach) |
Founded | 2014 |
Address | 12730 High Bluff Dr Suite 400, San Diego, California 92130, US |
Phone | (858) 500-8800 |
Technologies |
JavaScript,
HTML,
PHP
+39 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Drug discovery, Healthcare, Biotechnology, Cancer genetics, Health Care, Drug development, Science and Engineering, Anti-cancer medicines, Genetics, Medical |
Web Rank | 3 Million |
Keywords | Precision Medicine, Targeted Cancer Therapies, Cancer Treatment, Precision Oncology |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541715 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 5417 Companies, NAICS Code 32 Companies |
Looking for a particular Kura Oncology, Inc. employee's phone or email?
The Kura Oncology, Inc. annual revenue was $807000 in 2024.
Troy Wilson is the President and Chief Executive Officer of Kura Oncology, Inc..
143 people are employed at Kura Oncology, Inc..
Kura Oncology, Inc. is based in San Diego, California.
The NAICS codes for Kura Oncology, Inc. are [54171, 541715, 54, 541, 3254, 325, 5417, 32].
The SIC codes for Kura Oncology, Inc. are [283, 28].